Reiner Sabine Laus

US Patent:

6416958, Jul 9, 2002

Filed:

Aug 13, 2001

Appl. No.:

09/929209

Inventors:

Damir Vidovic - Bellevue WA
Reiner Laus - San Carlos CA

Assignee:

Dendreon Corporation - Seattle WA

International Classification:

G01N 3353

US Classification:

435 71, 435 4, 435 723

Abstract:

Anti-human major histocompatibility complex (MHC) class II, HLA-DR-specific monoclonal antibodies which can induce apoptosis of HLA-DR positive cells are disclosed. The antibodies are used to specifically eliminate HLA-DR antigen positive tumor cells by cross-linking of HLA-DR. Also disclosed are methods for treating cancer using such antibodies, and compositions containing them.

US Patent:

7060279, Jun 13, 2006

Filed:

Mar 30, 2001

Appl. No.:

09/821883

Inventors:

Reiner Laus - Bellevue WA, US
Damir Vidovic - Bellevue WA, US
Thomas Graddis - Seattle WA, US

Assignee:

Dendreon Corporation - Seattle WA

International Classification:

A61K 39/00

US Classification:

4241851, 4241921, 4242771, 435372, 435375, 530350

Abstract:

Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells pulsed with such an immunostimulatory fusion protein and methods for immunotherapy using the compositions.

US Patent:

7148324, Dec 12, 2006

Filed:

Dec 14, 1999

Appl. No.:

09/461684

Inventors:

Reiner Laus - Bellevue WA, US
Itzhak Hakim - Palo Alto CA, US
Damir Vidović - Bellevue WA, US

Assignee:

Dendreon Corporation - Seattle WA

International Classification:

C07K 1/00
C07K 14/00

US Classification:

530350, 530402, 530403

Abstract:

Compositions and methods for eliciting an in vivo cytotoxic lymphocyte (CTL) response against a modified soluble protein antigen are disclosed. The modified soluble protein antigen comprises an added peptidic sequence which facilitates entry of the modified antigen into antigen presenting cells (APC).

US Patent:

7414108, Aug 19, 2008

Filed:

Feb 4, 2004

Appl. No.:

10/772856

Inventors:

Reiner Laus - Bellevue WA, US
Curtis L. Ruegg - Redwood City CA, US
Michael H. Shapero - Redwood City CA, US
Demao Yang - Mountain View CA, US

Assignee:

Dendreon Corporation - Seattle WA

International Classification:

C07K 5/10

US Classification:

530350, 514 2

Abstract:

Disclosed are a novel prostatic acid phosphatase and corresponding coding region derived from mouse. Also disclosed is a method of producing an immune response against an autologous polypeptide tumor antigen by immunizing a subject with a xenogeneic polypeptide antigen, either alone, as part of a viral antigen construct, or as part of a pulsed dendritic cell preparation.

US Patent:

7560104, Jul 14, 2009

Filed:

Jun 16, 2006

Appl. No.:

11/455031

Inventors:

Reiner Laus - Bellevue WA, US
Itzhak Hakim - Palo Alto CA, US
Damir Vidović - Bellevue WA, US

Assignee:

Dendreon Corporation - Seattle WA

International Classification:

C12N 5/00
C12N 5/06
A61K 39/00

US Classification:

424 937, 424 9371, 435325

Abstract:

Compositions and methods for eliciting an in vivo cytotoxic lymphocyte (CTL) response against a modified soluble protein antigen are disclosed. The modified soluble protein antigen comprises an added peptidic sequence which facilitates entry of the modified antigen into antigen presenting cells (APC).

US Patent:

7597894, Oct 6, 2009

Filed:

Mar 5, 2004

Appl. No.:

10/794514

Inventors:

Thomas Graddis - Seattle WA, US
Reiner Laus - Bellevue WA, US
Michael Diegel - Covington WA, US
Damir Vidovic - Bellevue WA, US

Assignee:

Dendreon Corporation - Seattle WA

International Classification:

A61K 39/00

US Classification:

4241851, 530828

Abstract:

Provided are alternative reading frame (ARF) polypeptides as well as antigen presenting cell (APC) and dendritic cell (DC) based compositions and methods that employ alternative reading frame polypeptides. ARF polypeptides and ARF polypeptide-based compositions and methods are useful in the treatment of cancer and infectious disease.

US Patent:

7659117, Feb 9, 2010

Filed:

Jun 3, 2005

Appl. No.:

11/144912

Inventors:

Reiner Laus - Bellevue WA, US
Damir Vidovic - Bellevue WA, US
Thomas Graddis - Seattle WA, US

Assignee:

Dendreon Corporation - Seattle WA

International Classification:

C12N 5/06

US Classification:

435355, 435372, 530300, 530350

Abstract:

Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells pulsed with such an immunostimulatory fusion protein and methods for immunotherapy using the compositions.

US Patent:

7807146, Oct 5, 2010

Filed:

Oct 5, 2007

Appl. No.:

11/905876

Inventors:

Alain Delcayre - San Jose CA, US
Reiner Laus - Saratoga CA, US
Stefanie Mandl - San Francisco CA, US

Assignee:

BN Immunotherapeutics, Inc. - Mountain View CA

International Classification:

A61K 31/70
A61K 48/00
A01N 43/04

US Classification:

424 932, 514 44 R

Abstract:

The invention relates to compositions, kits, and methods for cancer therapy using recombinant MVA viruses encoding a tumor-associated antigen, such as HER-2, particularly in combination with taxanes. The taxanes can be administered prior to, at the same time as, or after the recombinant MVA virus.